Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01281111 · ClinicalTrials.gov registry record · Phase 1

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Biogen.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT01281111 is a Phase 1 study of Healthy that has completed, run by Biogen. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01281111, a Phase 1 study of Healthy, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of different doses and dosing regimens of BG00012 administered with and without ASA compared to placebo

Conditions Studied

Interventions

  • DRUG Aspirin
  • DRUG Dimethyl Fumarate (BG00012)
  • DRUG BG00012 matching placebo
  • DRUG ASA matching placebo

Study Locations (1)

Minnesota

  • Research Site - Saint Paul

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2011-02-01
Est. Completion 2011-03-18
Phase Phase 1

Sponsor

Biogen

334 total trials

What the Registry Record Tells You About NCT01281111

The ClinicalTrials.gov registry entry for NCT01281111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Aspirin is the first listed.

NCT01281111 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01281111 about?

NCT01281111 is a clinical study titled "Alternate Dosing Regimens of BG00012 in Healthy Volunteers". The purpose of this study is to evaluate the safety, tolerability, and PK of different doses and dosing regimens of BG00012 administered with and without ASA compared to placebo

What is the current status of trial NCT01281111?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2011-02-01. Estimated completion is 2011-03-18.

What conditions does trial NCT01281111 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01281111?

The interventions under investigation include: Aspirin (DRUG), Dimethyl Fumarate (BG00012) (DRUG), BG00012 matching placebo (DRUG), ASA matching placebo (DRUG).

Who is sponsoring clinical trial NCT01281111?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01281111 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.